METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
METiS Therapeutics (HKG: 7666) announced on August 31, 2026 a partnership with Jiangsu Hengrui Pharmaceuticals...
HKG: 7666
METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines
METiS TechBio (HKG: 7666) and WestVac Biopharma, an innovative vaccine and immunotherapy company led by...
METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
METiS TechBio (HKG: 7666) announced an exclusive global licensing agreement with Boulevard Bio, a U.S....